John Poirier

Title: John Poirier: Innovator in Cancer Therapeutics

Introduction

John Poirier is a notable inventor based in New York, NY (US), recognized for his contributions to cancer therapeutics. He holds a total of 4 patents that focus on innovative approaches to treating cancer. His work has significant implications for the field of oncology, particularly in the development of targeted therapies.

Latest Patents

Among his latest patents, one is titled "DLL3-targeting antibodies and uses thereof." This patent relates to immunoglobulin-related compositions, specifically antibodies that can bind to delta-like protein 3 (DLL3). These antibodies are instrumental in methods for detecting and treating DLL3-associated cancers in patients. Another significant patent is "Seneca Valley Virus (SVV) cellular receptor targeted oncotherapy." This patent outlines a method for selecting cancer patients for treatment with SVV by assessing the expression of ANTXR1 in cancerous tissues. If normal or elevated levels of ANTXR1 expression are detected, the patient is designated as a candidate for SVV treatment.

Career Highlights

John Poirier has worked with prestigious institutions, including Memorial Sloan Kettering Cancer Center and the Tri-Institutional Therapeutics Discovery Institute. His experience in these organizations has allowed him to contribute to groundbreaking research in cancer treatment.

Collaborations

Throughout his career, John has collaborated with esteemed colleagues such as Charles Rudin and Linde Miles. These partnerships have further enhanced his research and development efforts in the field of oncology.

Conclusion

John Poirier's innovative work in cancer therapeutics, particularly through his patents, showcases his commitment to advancing medical science. His contributions are paving the way for more effective cancer treatments and improving patient outcomes.